Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer
Abstract
Overexpression of myeloid cell leukemia-1 (Mcl-1) in cancers correlates with high tumor grade and poor survival. Further, Mcl-1 drives intrinsic and acquired resistance to many cancer therapeutics, including B cell lymphoma 2 family inhibitors, proteasome inhibitors, and antitubulins. Therefore, Mcl-1 inhibition could serve as a strategy to target cancers that require Mcl-1 to evade apoptosis. Herein, we describe the use of structure-based design to discover a novel compound (42) that robustly and specifically inhibits Mcl-1 in cell culture and animal xenograft models. Compound 42 binds to Mcl-1 with picomolar affinity and inhibited growth of Mcl-1-dependent tumor cell lines in the nanomolar range. Compound 42 also inhibited the growth of hematological and triple negative breast cancer xenografts at well-tolerated doses. These findings highlight the use of structure-based design to identify small molecule Mcl-1 inhibitors and support the use of 42 as a potential treatment strategy to block Mcl-1 activity and induce apoptosis in Mcl-1-dependent cancers.
- Authors:
-
more »
- Vanderbilt Univ. School of Medicine, Nashville, TN (United States)
- Vanderbilt Univ., Nashville, TN (United States)
- Vanderbilt-Ingram Cancer Center, Nashville, TN (United States)
- National Cancer Institute, Bethesda, MD (United States)
- St. Jude Children’s Research Hospital, Memphis, TN (United States)
- Frederick National Lab. for Cancer Research, MD (United States)
- Publication Date:
- Research Org.:
- Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
- Sponsoring Org.:
- USDOE Office of Science (SC), Basic Energy Sciences (BES); National Institutes of Health (NIH); National Cancer Institute (NCI); E. P. Evans Foundation; Biff Ruttenberg Foundation; Vanderbilt-Ingram Cancer Center; Vanderbilt Digestive Disease Research Center
- OSTI Identifier:
- 1515302
- Grant/Contract Number:
- HHSN261200800001E; P50CA098131; AC02-06CH11357; S10 RR026915
- Resource Type:
- Accepted Manuscript
- Journal Name:
- Journal of Medicinal Chemistry
- Additional Journal Information:
- Journal Volume: 62; Journal Issue: 8; Journal ID: ISSN 0022-2623
- Publisher:
- American Chemical Society (ACS)
- Country of Publication:
- United States
- Language:
- ENGLISH
- Subject:
- 60 APPLIED LIFE SCIENCES; Cancer; Rodent models; Cells; Inhibitors; Screening assays
Citation Formats
Lee, Taekyu, Christov, Plamen P., Shaw, Subrata, Tarr, James C., Zhao, Bin, Veerasamy, Nagarathanam, Jeon, Kyu Ok, Mills, Jonathan J., Bian, Zhiguo, Sensintaffar, John L., Arnold, Allison L., Fogarty, Stuart A., Perry, Evan, Ramsey, Haley E., Cook, Rebecca S., Hollingshead, Melinda, Davis Millin, Myrtle, Lee, Kyung-min, Koss, Brian, Budhraja, Amit, Opferman, Joseph T., Kim, Kwangho, Arteaga, Carlos L., Moore, William J., Olejniczak, Edward T., Savona, Michael R., and Fesik, Stephen W. Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer. United States: N. p., 2019.
Web. doi:10.1021/acs.jmedchem.8b01991.
Lee, Taekyu, Christov, Plamen P., Shaw, Subrata, Tarr, James C., Zhao, Bin, Veerasamy, Nagarathanam, Jeon, Kyu Ok, Mills, Jonathan J., Bian, Zhiguo, Sensintaffar, John L., Arnold, Allison L., Fogarty, Stuart A., Perry, Evan, Ramsey, Haley E., Cook, Rebecca S., Hollingshead, Melinda, Davis Millin, Myrtle, Lee, Kyung-min, Koss, Brian, Budhraja, Amit, Opferman, Joseph T., Kim, Kwangho, Arteaga, Carlos L., Moore, William J., Olejniczak, Edward T., Savona, Michael R., & Fesik, Stephen W. Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer. United States. https://doi.org/10.1021/acs.jmedchem.8b01991
Lee, Taekyu, Christov, Plamen P., Shaw, Subrata, Tarr, James C., Zhao, Bin, Veerasamy, Nagarathanam, Jeon, Kyu Ok, Mills, Jonathan J., Bian, Zhiguo, Sensintaffar, John L., Arnold, Allison L., Fogarty, Stuart A., Perry, Evan, Ramsey, Haley E., Cook, Rebecca S., Hollingshead, Melinda, Davis Millin, Myrtle, Lee, Kyung-min, Koss, Brian, Budhraja, Amit, Opferman, Joseph T., Kim, Kwangho, Arteaga, Carlos L., Moore, William J., Olejniczak, Edward T., Savona, Michael R., and Fesik, Stephen W. Sat .
"Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer". United States. https://doi.org/10.1021/acs.jmedchem.8b01991. https://www.osti.gov/servlets/purl/1515302.
@article{osti_1515302,
title = {Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer},
author = {Lee, Taekyu and Christov, Plamen P. and Shaw, Subrata and Tarr, James C. and Zhao, Bin and Veerasamy, Nagarathanam and Jeon, Kyu Ok and Mills, Jonathan J. and Bian, Zhiguo and Sensintaffar, John L. and Arnold, Allison L. and Fogarty, Stuart A. and Perry, Evan and Ramsey, Haley E. and Cook, Rebecca S. and Hollingshead, Melinda and Davis Millin, Myrtle and Lee, Kyung-min and Koss, Brian and Budhraja, Amit and Opferman, Joseph T. and Kim, Kwangho and Arteaga, Carlos L. and Moore, William J. and Olejniczak, Edward T. and Savona, Michael R. and Fesik, Stephen W.},
abstractNote = {Overexpression of myeloid cell leukemia-1 (Mcl-1) in cancers correlates with high tumor grade and poor survival. Further, Mcl-1 drives intrinsic and acquired resistance to many cancer therapeutics, including B cell lymphoma 2 family inhibitors, proteasome inhibitors, and antitubulins. Therefore, Mcl-1 inhibition could serve as a strategy to target cancers that require Mcl-1 to evade apoptosis. Herein, we describe the use of structure-based design to discover a novel compound (42) that robustly and specifically inhibits Mcl-1 in cell culture and animal xenograft models. Compound 42 binds to Mcl-1 with picomolar affinity and inhibited growth of Mcl-1-dependent tumor cell lines in the nanomolar range. Compound 42 also inhibited the growth of hematological and triple negative breast cancer xenografts at well-tolerated doses. These findings highlight the use of structure-based design to identify small molecule Mcl-1 inhibitors and support the use of 42 as a potential treatment strategy to block Mcl-1 activity and induce apoptosis in Mcl-1-dependent cancers.},
doi = {10.1021/acs.jmedchem.8b01991},
journal = {Journal of Medicinal Chemistry},
number = 8,
volume = 62,
place = {United States},
year = {Sat Mar 30 00:00:00 EDT 2019},
month = {Sat Mar 30 00:00:00 EDT 2019}
}
Web of Science
Works referenced in this record:
Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines
journal, February 2016
- Koss, Brian; Ryan, Jeremy; Budhraja, Amit
- Oncotarget, Vol. 7, Issue 10
Discovery of Tricyclic Indoles That Potently Inhibit Mcl-1 Using Fragment-Based Methods and Structure-Based Design
journal, April 2015
- Burke, Jason P.; Bian, Zhiguo; Shaw, Subrata
- Journal of Medicinal Chemistry, Vol. 58, Issue 9
Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells
journal, July 2002
- Derenne, Sophie; Monia, Brett; Dean, Nicholas M.
- Blood, Vol. 100, Issue 1
Three-dimensional structures of proteins involved in programmed cell death
journal, December 1997
- Liang, Heng; Fesik, Stephen W.
- Journal of Molecular Biology, Vol. 274, Issue 3
Chemical Genomics Identifies Small-Molecule MCL1 Repressors and BCL-xL as a Predictor of MCL1 Dependency
journal, April 2012
- Wei, Guo; Margolin, Adam A.; Haery, Leila
- Cancer Cell, Vol. 21, Issue 4
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
journal, October 2016
- Kotschy, András; Szlavik, Zoltán; Murray, James
- Nature, Vol. 538, Issue 7626
The BCL-2 protein family, BH3-mimetics and cancer therapy
journal, May 2015
- Delbridge, A. R. D.; Strasser, A.
- Cell Death & Differentiation, Vol. 22, Issue 7
Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19 ARF
journal, November 1997
- Kamijo, Takehiko; Zindy, Frederique; Roussel, Martine F.
- Cell, Vol. 91, Issue 5
Mechanism of Synergy of N-(4-Hydroxyphenyl)Retinamide and ABT-737 in Acute Lymphoblastic Leukemia Cell Lines: Mcl-1 Inactivation
journal, April 2008
- Kang, Min H.; Wan, Zesheng; Kang, Yun Hee
- JNCI: Journal of the National Cancer Institute, Vol. 100, Issue 8
Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia
journal, July 2014
- Kaefer, Aksana; Yang, Jianning; Noertersheuser, Peter
- Cancer Chemotherapy and Pharmacology, Vol. 74, Issue 3
Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia
journal, August 2013
- Koss, Brian; Morrison, Jeffrey; Perciavalle, Rhonda M.
- Blood, Vol. 122, Issue 9
Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization
journal, September 2004
- Nikolovska-Coleska, Zaneta; Wang, Renxiao; Fang, Xueliang
- Analytical Biochemistry, Vol. 332, Issue 2
Structural biology of the Bcl-2 family of proteins
journal, March 2004
- Petros, Andrew M.; Olejniczak, Edward T.; Fesik, Stephen W.
- Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, Vol. 1644, Issue 2-3
The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer
journal, June 2010
- Stewart, Michelle L.; Fire, Emiko; Keating, Amy E.
- Nature Chemical Biology, Vol. 6, Issue 8
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
journal, December 2013
- Czabotar, Peter E.; Lessene, Guillaume; Strasser, Andreas
- Nature Reviews Molecular Cell Biology, Vol. 15, Issue 1
Bcl-2 and the regulation of programmed cell death
journal, January 1994
- Reed, J. C.
- The Journal of Cell Biology, Vol. 124, Issue 1
Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors
journal, January 2017
- Johannes, Jeffrey W.; Bates, Stephanie; Beigie, Carl
- ACS Medicinal Chemistry Letters, Vol. 8, Issue 2
Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1
journal, December 2003
- Opferman, Joseph T.; Letai, Anthony; Beard, Caroline
- Nature, Vol. 426, Issue 6967
Bcl-2 inhibitors: small molecules with a big impact on cancer therapy
journal, September 2008
- Vogler, M.; Dinsdale, D.; Dyer, M. J. S.
- Cell Death & Differentiation, Vol. 16, Issue 3
The landscape of somatic copy-number alteration across human cancers
journal, February 2010
- Beroukhim, Rameen; Mermel, Craig H.; Porter, Dale
- Nature, Vol. 463, Issue 7283
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7
journal, March 2011
- Wertz, Ingrid E.; Kusam, Saritha; Lam, Cynthia
- Nature, Vol. 471, Issue 7336
A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia
journal, September 2018
- Ramsey, Haley E.; Fischer, Melissa A.; Lee, Taekyu
- Cancer Discovery, Vol. 8, Issue 12
Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells
journal, March 2005
- Song, Lanxi; Coppola, Domenico; Livingston, Sandy
- Cancer Biology & Therapy, Vol. 4, Issue 3
The Bcl-2 apoptotic switch in cancer development and therapy
journal, February 2007
- Adams, J. M.; Cory, S.
- Oncogene, Vol. 26, Issue 9
A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy
journal, May 2010
- Placzek, W. J.; Wei, J.; Kitada, S.
- Cell Death & Disease, Vol. 1, Issue 5
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
journal, April 2004
- Arkin, Michelle R.; Wells, James A.
- Nature Reviews Drug Discovery, Vol. 3, Issue 4
Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods
journal, February 2016
- Pelz, Nicholas F.; Bian, Zhiguo; Zhao, Bin
- Journal of Medicinal Chemistry, Vol. 59, Issue 5
Bcl-x L and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis
journal, January 2009
- Brotin, Emilie; Meryet-Figuière, Matthieu; Simonin, Karin
- International Journal of Cancer
Caspase-dependent apoptosis of COS-7 cells induced by Bax overexpression: differential effects of Bcl-2 and Bcl-xL on Bax-induced caspase activation and apoptosis
journal, October 1997
- Kitanaka, Chifumi; Namiki, Takahiro; Noguchi, Kohji
- Oncogene, Vol. 15, Issue 15
Essential role of BAX,BAK in B cell homeostasis and prevention of autoimmune disease
journal, July 2005
- Takeuchi, O.; Fisher, J.; Suh, H.
- Proceedings of the National Academy of Sciences, Vol. 102, Issue 32
Myeloid Cell Leukemia-1 Inversely Correlates with Glycogen Synthase Kinase-3β Activity and Associates with Poor Prognosis in Human Breast Cancer
journal, May 2007
- Ding, Qingqing; He, Xianghuo; Xia, Weiya
- Cancer Research, Vol. 67, Issue 10
Structural insights into the degradation of Mcl-1 induced by BH3 domains
journal, March 2007
- Czabotar, P. E.; Lee, E. F.; van Delft, M. F.
- Proceedings of the National Academy of Sciences, Vol. 104, Issue 15
Optimization of Potent and Selective Tricyclic Indole Diazepinone Myeloid Cell Leukemia-1 Inhibitors Using Structure-Based Design
journal, January 2018
- Shaw, Subrata; Bian, Zhiguo; Zhao, Bin
- Journal of Medicinal Chemistry, Vol. 61, Issue 6
Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors
journal, December 2016
- Lee, Taekyu; Bian, Zhiguo; Zhao, Bin
- FEBS Letters, Vol. 591, Issue 1
Discovery of Potent Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods and Structure-Based Design
journal, December 2012
- Friberg, Anders; Vigil, Dominico; Zhao, Bin
- Journal of Medicinal Chemistry, Vol. 56, Issue 1
Designed BH3 Peptides with High Affinity and Specificity for Targeting Mcl-1 in Cells
journal, July 2014
- Foight, Glenna Wink; Ryan, Jeremy A.; Gullá, Stefano V.
- ACS Chemical Biology, Vol. 9, Issue 9
The Hallmarks of Cancer
journal, January 2000
- Hanahan, Douglas; Weinberg, Robert A.
- Cell, Vol. 100, Issue 1
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
journal, January 2013
- Souers, Andrew J.; Leverson, Joel D.; Boghaert, Erwin R.
- Nature Medicine, Vol. 19, Issue 2
Immunohistochemical Analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 Expression in Pancreatic Cancers
journal, January 1999
- Miyamoto, Yoshiharu; Hosotani, Ryo; Wada, Michihiko
- Oncology, Vol. 56, Issue 1
The antiapoptotic member of the Bcl-2 family Mcl-1 is a CTL target in cancer patients
journal, December 2004
- Andersen, M. H.; Becker, J. C.; thor Straten, P.
- Leukemia, Vol. 19, Issue 3
Inducing apoptosis and enhancing chemosensitivity to Gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell
journal, February 2008
- Wei, San-Hua; Dong, Ke; Lin, Fang
- Cancer Chemotherapy and Pharmacology, Vol. 62, Issue 6
Works referencing / citing this record:
MCL-1 inhibitors – where are we now (2019)?
journal, October 2019
- Fletcher, Steven
- Expert Opinion on Therapeutic Patents, Vol. 29, Issue 11
Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers
journal, September 2019
- Williams, Michelle M.; Elion, David L.; Rahman, Bushra
- Oncotarget, Vol. 10, Issue 52